NO20063373L - CD40-antistoff-formuleringer og fremgangsmater - Google Patents

CD40-antistoff-formuleringer og fremgangsmater

Info

Publication number
NO20063373L
NO20063373L NO20063373A NO20063373A NO20063373L NO 20063373 L NO20063373 L NO 20063373L NO 20063373 A NO20063373 A NO 20063373A NO 20063373 A NO20063373 A NO 20063373A NO 20063373 L NO20063373 L NO 20063373L
Authority
NO
Norway
Prior art keywords
methods
patient
antibody formulations
administering
tumor
Prior art date
Application number
NO20063373A
Other languages
English (en)
Other versions
NO343797B1 (no
Inventor
Ronald Paul Gladue
Vahe Bedian
John Daniel Cusmano
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34738672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20063373(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20063373L publication Critical patent/NO20063373L/no
Publication of NO343797B1 publication Critical patent/NO343797B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Abstract

Det beskrives en fremgangsmåte for behandling av tumor hos en pasient, omfattende administrering til pasienten av et CD40 agonist antistoff i henhold til en intermittent doseringsplan. Det beskrives videre en fremgangsmåte for behandling av tumor i en pasient omfattende administrering av en kombinasjon av et CD40 agonist antistoff og en DNA replikasjonsinhibitor. Det beskrives videre en formulering for bruk ved slik behandling.
NO20063373A 2003-12-22 2006-07-20 Flytende farmasøytisk formulering inneholdende CD40-antistoff og anvendelse av slike. NO343797B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53163903P 2003-12-22 2003-12-22
PCT/IB2004/004103 WO2005063289A1 (en) 2003-12-22 2004-12-09 Cd40 antibody formulation and methods

Publications (2)

Publication Number Publication Date
NO20063373L true NO20063373L (no) 2006-09-21
NO343797B1 NO343797B1 (no) 2019-06-11

Family

ID=34738672

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063373A NO343797B1 (no) 2003-12-22 2006-07-20 Flytende farmasøytisk formulering inneholdende CD40-antistoff og anvendelse av slike.

Country Status (20)

Country Link
US (4) US20050136055A1 (no)
EP (3) EP2218461B1 (no)
JP (3) JP2007515469A (no)
KR (2) KR100847944B1 (no)
CN (2) CN102552905A (no)
AU (1) AU2004308749B2 (no)
BR (1) BRPI0418029B8 (no)
CA (2) CA2704300A1 (no)
DK (1) DK2218461T3 (no)
ES (1) ES2580002T3 (no)
HU (1) HUE027717T2 (no)
IL (2) IL175540A (no)
NO (1) NO343797B1 (no)
NZ (2) NZ547162A (no)
PL (1) PL2218461T3 (no)
RU (1) RU2355421C2 (no)
SI (1) SI2218461T1 (no)
TW (1) TWI359671B (no)
WO (1) WO2005063289A1 (no)
ZA (1) ZA200603804B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20090304687A1 (en) * 2005-12-09 2009-12-10 Seattle Genetics , Inc. Methods of using cd40 binding agents
WO2007130493A2 (en) 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2735421A1 (en) * 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
US9561214B2 (en) * 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
BR112013027829B1 (pt) 2011-04-29 2022-05-10 Apexigen, Inc Anticorpos anti-cd40 ou fragmentos de ligação aos antígenos destes, composição que compreende os ditos anticorpos e uso da dita composição para tratar ou melhorar os sintomas de câncer, doença autoimune ou doença inflamatória
SG10201603896RA (en) 2012-05-04 2016-07-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
NZ707086A (en) 2012-10-30 2019-07-26 Apexigen Inc Anti-cd40 antibodies and methods of use
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
EP2951209A4 (en) 2013-01-31 2016-06-22 Univ Jefferson CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF
EP4269441A3 (en) 2013-08-08 2024-01-24 Cytune Pharma Il-15 and il-15ralpha sushi domain based on modulokines
JP6691113B2 (ja) 2014-10-29 2020-04-28 シアトル ジェネティックス， インコーポレイテッド 非フコシル化抗ｃｄ４０抗体の投与量および投与
BR112018000903A2 (pt) 2015-07-16 2018-09-11 Biokine Therapeutics Ltd. composições e métodos para o tratamento de câncer
CN108778301A (zh) 2016-03-10 2018-11-09 永恒生物科技股份有限公司 通过联合疗法来治疗实体瘤或淋巴瘤的方法
JP7148504B2 (ja) 2016-06-08 2022-10-05 ゼンコー，インコーポレイティド ＣＤ３２Ｂに交差結合した抗ＣＤ１９抗体を用いたＩｇＧ４関連疾患の治療
CN109475603B (zh) 2016-06-20 2023-06-13 科马布有限公司 抗pd-l1抗体
WO2018088850A2 (ko) * 2016-11-11 2018-05-17 다이노나(주) Cd40에 특이적으로 결합하는 항체 및 그의 용도
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
US11242397B2 (en) 2017-06-01 2022-02-08 Pb Immune Therapeutics Inc. Anti-CD40 antibody and methods for blocking CD40-CD40L signaling
TW201902462A (zh) * 2017-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 用於免疫促效劑之新穎投與途徑
EP3418302A1 (en) * 2017-06-19 2018-12-26 F. Hoffmann-La Roche AG Administration routes for immune agonists
EP3781203A4 (en) * 2018-04-20 2022-04-13 Lyvgen Biopharma Co., Ltd. ANTI-CD40 ANTIBODIES AND USES THEREOF
MA52889A (fr) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
CN116063495A (zh) * 2018-09-28 2023-05-05 礼进生物医药科技（上海）有限公司 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
BR112021010414A2 (pt) 2018-11-30 2021-09-08 Jiangsu Hengrui Medicine Co., Ltd. Composição farmacêutica compreendendo um anticorpo cd40, método para preparar uma preparação liofilizada, preparação liofilizada, uso das mesmas e produto que compreende um recipiente contendo as mesmas
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
WO2022006179A1 (en) 2020-06-29 2022-01-06 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
EP4175673A1 (en) 2020-07-01 2023-05-10 ARS Pharmaceuticals Inc. Anti-asgr1 antibody conjugates and uses thereof
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
JP2547556B2 (ja) * 1987-02-06 1996-10-23 株式会社 ミドリ十字 ｒ−グロブリンの液状製剤
SE8701004D0 (sv) 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
JPH03204821A (ja) * 1989-12-28 1991-09-06 Green Cross Corp:The モノクローナル抗体含有水溶液の加熱処理方法
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
AU5098493A (en) 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
KR960704576A (ko) * 1993-10-01 1996-10-09 크리스토퍼 엘. 와이트 CD40에 대한 항체(Antibodies to CD40)
NZ278740A (en) * 1993-12-23 1998-05-27 Immunex Corp Treating disease characterised by neoplastic cells expressing cd40 using a cd40 binding protein
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1998056418A1 (en) * 1997-06-13 1998-12-17 Genentech, Inc. Stabilized antibody formulation
ES2529706T3 (es) * 1999-06-01 2015-02-24 Biogen Idec Ma Inc. Un anticuerpo monoclonal bloqueante contra el dominio alfa1-I de VLA-1, y su uso para el tratamiento de trastornos inflamatorios
US6358670B1 (en) * 1999-12-28 2002-03-19 Electron Vision Corporation Enhancement of photoresist plasma etch resistance via electron beam surface cure
JP4516711B2 (ja) * 1999-12-28 2010-08-04 中外製薬株式会社 安定な抗体組成物及び注射製剤
BR0108001A (pt) 2000-02-01 2004-01-06 Tanox Inc Moléculas ativadoras de apc com ligação para cd-40
WO2001074388A1 (en) * 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
US7063845B2 (en) * 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
AU2001296507A1 (en) * 2000-10-02 2002-04-15 Chiron Corporation Human anti-cd40 antibodies
EP1324776B2 (en) * 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
US20030113316A1 (en) * 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
ES2392073T3 (es) * 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2467633C (en) * 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
US7115108B2 (en) 2002-04-02 2006-10-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US20080009439A1 (en) * 2002-11-05 2008-01-10 Alsobrook John P Compositions and Methods of Use for a Fibroblast Growth Factor
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET

Also Published As

Publication number Publication date
US20120263732A1 (en) 2012-10-18
IL175540A (en) 2011-10-31
BRPI0418029B8 (pt) 2021-05-25
ZA200603804B (en) 2007-09-26
JP2007515469A (ja) 2007-06-14
IL175540A0 (en) 2006-09-05
TWI359671B (en) 2012-03-11
US20090311254A1 (en) 2009-12-17
AU2004308749B2 (en) 2010-10-28
KR20080023766A (ko) 2008-03-14
NO343797B1 (no) 2019-06-11
EP1706143A1 (en) 2006-10-04
ES2580002T3 (es) 2016-08-18
AU2004308749A1 (en) 2005-07-14
RU2006120950A (ru) 2008-01-27
KR100847944B1 (ko) 2008-07-22
BRPI0418029A (pt) 2007-04-17
DK2218461T3 (en) 2016-05-17
CN1897971A (zh) 2007-01-17
HUE027717T2 (en) 2016-10-28
TW200521142A (en) 2005-07-01
EP2218461B1 (en) 2016-04-20
RU2355421C2 (ru) 2009-05-20
NZ547162A (en) 2010-03-26
PL2218461T3 (pl) 2016-09-30
EP2218461A1 (en) 2010-08-18
US20050136055A1 (en) 2005-06-23
CA2549652C (en) 2013-11-12
KR20070012626A (ko) 2007-01-26
CA2704300A1 (en) 2005-07-14
US20110104182A1 (en) 2011-05-05
JP2011184446A (ja) 2011-09-22
SI2218461T1 (sl) 2016-08-31
CA2549652A1 (en) 2005-07-14
IL201409A0 (en) 2010-05-31
NZ583179A (en) 2011-06-30
WO2005063289A1 (en) 2005-07-14
JP5634321B2 (ja) 2014-12-03
JP2014205692A (ja) 2014-10-30
BRPI0418029B1 (pt) 2018-12-26
EP3081933A1 (en) 2016-10-19
CN102552905A (zh) 2012-07-11

Similar Documents

Publication Publication Date Title
NO20063373L (no) CD40-antistoff-formuleringer og fremgangsmater
ATE312635T1 (de) Ventilanordnung
NO20026171L (no) Topiske farmasöytiske formuleringer og fremgangsmåter for behandling
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
DE60323090D1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
GEP20053511B (en) ) β-Carboline Derivatives Useful as Inhibitors of Phosphodiesterase
HUP0401867A2 (hu) A valproinsav-amid és a 2-valproénsav-amid származékainak használata a fájdalommal és a fejfájással járó betegségek kezelésére vagy megelőzésére
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
CY1107352T1 (el) Προεγχειρητικη θεραπευτικη αγωγη μετεγχειρητικου πονου
NO20101070L (no) Fremgangsmate til dosering av et medikament, samt doseringsform
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
DK1397681T3 (da) Fremgangsmåde til identificering af midler til behandling af diabetes
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
DK1343472T3 (da) Thixotropisk næsespray
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
NO20052313L (no) Vandig farmasoytisk formulering omfattende trombininhibitorer melagatran og anvendelse av formuleringen for fremstilling av et medikament for anvendelse i nasal administrering i behandling av
SE0102887D0 (sv) New formulation
EA200401454A1 (ru) Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний
DE602004029993D1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
ATE407925T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
ATE337783T1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
WO2004035030A3 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain
ATE338560T1 (de) Pharmazeutische zusammentsetzung zur medizinischen behandlung von gutartiger prostathyperplasie, dessen vorbereitungsmethode und dessen therapeutische verwendung
ATE402147T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees